Why emodepside formulation matters in dogs with resistant hookworms

A new AJVR study is giving veterinarians firmer evidence that emodepside formulation can’t be treated as interchangeable when managing hard-to-clear canine hookworm cases. Researchers reported that the FDA-approved feline topical emodepside/praziquantel solution, when administered orally to dogs at 1 mg/kg, was not bioequivalent to the European Medicines Agency-approved canine modified-release tablet at the same dose. Oral dosing of the feline topical solution led to markedly greater absorption, while topical administration of that same feline product yielded far lower systemic exposure. On the AVMA’s Veterinary Vertex podcast, the authors put numbers to that difference: the orally administered feline product produced an approximately 3-fold higher Cmax and 2.4- to 2.8-fold greater AUC than the canine tablet. (pubmed.ncbi.nlm.nih.gov; veterinaryvertex.buzzsprout.com)

The issue has been building for several years as multidrug-resistant Ancylostoma caninum has complicated treatment in some dogs, particularly in high-risk populations such as racing and adoption greyhounds. Earlier work and clinical discussion had pointed to emodepside as one of the few remaining effective options in some refractory cases, even though no canine emodepside product is approved in the US. That gap helped drive extra-label oral use of the feline topical product in dogs, which researchers on the AVMA’s Veterinary Vertex podcast said was exactly what raised their safety concerns. In that discussion, the authors also noted that emodepside is part of the octadepsipeptide class, with a mechanism distinct from other antiparasitics currently on the market—part of why it has attracted interest in resistant nematode infections. (vtechworks.lib.vt.edu; veterinaryvertex.buzzsprout.com)

In the new study, seven healthy client-owned dogs completed a three-phase crossover trial between May and August 2023. Dogs received the feline topical solution orally at 1 mg/kg, the canine modified-release tablet orally at 1 mg/kg, and the feline topical solution topically at 3 mg/kg, with plasma pharmacokinetics tracked for 21 days. The key finding was that oral administration of the feline topical product resulted in much higher emodepside exposure than the canine tablet and therefore failed bioequivalence criteria. As the authors explained on the podcast, bioequivalence under FDA standards means products are comparable in both the rate and extent of absorption; these two were not. Meanwhile, topical use of the feline product in dogs produced emodepside plasma concentrations 36- to 122-fold lower than oral administration, which the authors said suggests poor suitability for treating multidrug-resistant hookworm infections. (pubmed.ncbi.nlm.nih.gov; veterinaryvertex.buzzsprout.com)

That matters because emodepside has been discussed as a last-line option after failure of combination protocols. A recent guidance document on persistent suspected-resistant hookworm infections described oral emodepside at 1 mg/kg with praziquantel as the only potentially effective alternative if triple-combination approaches fail, citing 99.6% efficacy and a 100% reduction in fecal egg counts at 10 days in prior work. But that same document also emphasized that precise dosing is critical, that the feline label cannot be used to estimate a canine dose, and that administration should occur in-clinic rather than being dispensed to the pet parent for home use. (assets.takeshape.io)

Outside experts and trade coverage had already been warning clinicians to move carefully. AAHA’s coverage of extra-label emodepside use highlighted recommendations to confirm treatment failure with fecal egg count reduction testing first, consider fecal PCR where appropriate, screen for heartworm disease, and assess MDR1 status in at-risk dogs. The article also noted concern that some dogs may require repeated dosing, while stressing that long-term use is not advised and that environmental control remains essential to reduce reinfection. (aaha.org)

The safety question is especially important because emodepside is a P-glycoprotein substrate. On the Veterinary Vertex episode tied to the paper, the authors noted that dogs with MDR1-related transporter dysfunction may be at higher risk for neurotoxicity because the drug can accumulate in the brain. Broader review literature supports that mechanism, describing how impaired P-glycoprotein function can allow greater CNS penetration of emodepside. FDA approval documents for the feline topical product also show that oral exposure in cats caused adverse effects including salivation and vomiting, with transient neurologic and respiratory signs reported in a pilot oral safety study. Those feline data aren’t directly translatable to dogs, but they reinforce why route and formulation changes deserve caution. (veterinaryvertex.buzzsprout.com)

Why it matters: For veterinarians, the takeaway is less about whether emodepside has a role and more about how narrow that role may need to be. In suspected multidrug-resistant hookworm cases, this study argues against assuming that a feline topical product given orally is a stand-in for a canine oral formulation, and it raises the stakes for dose calculation, patient selection, informed consent, and monitoring. It also underscores a broader pharmacology principle with real clinical consequences: formulation differences can alter exposure enough to change both efficacy and safety. (pubmed.ncbi.nlm.nih.gov; veterinaryvertex.buzzsprout.com)

What to watch: The next questions are whether larger canine safety studies, breed- or genotype-specific risk assessments, and more standardized treatment algorithms emerge, and whether US clinicians increasingly reserve extra-label emodepside for tightly selected cases after documented failure of combination therapy and specialist consultation. (pubmed.ncbi.nlm.nih.gov)